BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang TY, Chang TC, Chin YT, Pan YS, Chang WJ, Liu FC, Hastuti ED, Chiu SJ, Wang SH, Changou CA, Li ZL, Chen YR, Chu HR, Shih YJ, Cheng RH, Wu A, Lin HY, Wang K, Whang-Peng J, Mousa SA, Davis PJ. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer. Cells 2020;9:E1830. [PMID: 32756527 DOI: 10.3390/cells9081830] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Yang YSH, Ko PJ, Pan YS, Lin HY, Whang-Peng J, Davis PJ, Wang K. Role of thyroid hormone-integrin αvβ3-signal and therapeutic strategies in colorectal cancers. J Biomed Sci 2021;28:24. [PMID: 33827580 DOI: 10.1186/s12929-021-00719-5] [Reference Citation Analysis]
2 Cui Y, Zhang C, Ma S, Guan F. TFAP2A-induced SLC2A1-AS1 promotes cancer cell proliferation. Biol Chem 2021;402:717-27. [PMID: 33580997 DOI: 10.1515/hsz-2020-0290] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol 2021;14:10. [PMID: 33413496 DOI: 10.1186/s13045-020-01027-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 18.0] [Reference Citation Analysis]
4 Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, Zeng WJ, Liu Z, Cheng Q. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res 2021;40:184. [PMID: 34088360 DOI: 10.1186/s13046-021-01987-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
5 Godugu K, Rajabi M, Mousa SA. Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers (Basel) 2021;13:2780. [PMID: 34204997 DOI: 10.3390/cancers13112780] [Reference Citation Analysis]
6 Cheng TM, Chang WJ, Chu HY, De Luca R, Pedersen JZ, Incerpi S, Li ZL, Shih YJ, Lin HY, Wang K, Whang-Peng J. Nano-Strategies Targeting the Integrin αvβ3 Network for Cancer Therapy. Cells 2021;10:1684. [PMID: 34359854 DOI: 10.3390/cells10071684] [Reference Citation Analysis]
7 Deligiorgi MV, Trafalis DT. The Intriguing Thyroid Hormones-Lung Cancer Association as Exemplification of the Thyroid Hormones-Cancer Association: Three Decades of Evolving Research. Int J Mol Sci 2021;23:436. [PMID: 35008863 DOI: 10.3390/ijms23010436] [Reference Citation Analysis]
8 Liu Z, Li C, Yu C, Chen Z, Zhao C, Ye L. TSPYL2 reduced gefitinib resistance and DNA damage repair via suppressing SIRT1-mediated FOXO3 deacetylation. Future Med Chem 2022. [PMID: 35192400 DOI: 10.4155/fmc-2021-0136] [Reference Citation Analysis]
9 Chung CC, Huang TY, Chu HR, De Luca R, Candelotti E, Huang CH, Yang YSH, Incerpi S, Pedersen JZ, Lin CY, Huang HM, Lee SY, Li ZL, ChangOu CA, Li WS, Davis PJ, Lin HY, Whang-Peng J, Wang K. Heteronemin and tetrac derivatives suppress non-small cell lung cancer growth via ERK1/2 inhibition. Food Chem Toxicol 2022;:112850. [PMID: 35151786 DOI: 10.1016/j.fct.2022.112850] [Reference Citation Analysis]